Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age.
AIDS
; 33(11): 1797-1799, 2019 09 01.
Article
em En
| MEDLINE
| ID: mdl-31149946
ABSTRACT
Use of dolutegravir-based first-line antiretroviral therapy (ART) in response to rising levels of pretreatment HIV drug resistance (PDR) to non-nucleoside reverse transcriptase inhibitors (NNRTIs) may be limited, given safety concerns for birth defects in women of child-bearing potential. Pooled data from 11 nationally representative surveys show that NNRTI PDR in women is nearly twice that in men, exceeding 10% in 8 of 11 countries monitored, suggesting the urgent need for a non-NNRTI-based ART regimen in this population.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
Inibidores da Transcriptase Reversa
/
Farmacorresistência Viral
/
Compostos Heterocíclicos com 3 Anéis
Limite:
Female
/
Humans
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article